These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 34408401)

  • 21. Two new compounds from the aerial parts of Bergenia himalaica Boriss and their anti-hyperglycemic effect in streptozotocin-nicotinamide induced diabetic rats.
    Siddiqui BS; Hasan M; Mairaj F; Mehmood I; Hafizur RM; Hameed A; Khan Shinwari Z
    J Ethnopharmacol; 2014 Mar; 152(3):561-7. PubMed ID: 24534525
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of PEGylated FGF-21 with insulin glargine for long-lasting hypoglycaemic effect in db/db mice.
    Ye X; Qi J; Wu Y; Yu D; Xu P; Li S; Zhu S; Wu Q; Ren G; Li D
    Diabetes Metab; 2015 Feb; 41(1):82-90. PubMed ID: 25451186
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vivo performance and biocompatibility of a subcutaneous implant for real-time glucose-responsive insulin delivery.
    Chu MK; Gordijo CR; Li J; Abbasi AZ; Giacca A; Plettenburg O; Wu XY
    Diabetes Technol Ther; 2015 Apr; 17(4):255-67. PubMed ID: 25671341
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacodynamics of the long-acting insulin analogues detemir and glargine following single-doses and under steady-state conditions in patients with type 1 diabetes.
    Koehler G; Treiber G; Wutte A; Korsatko S; Mader JK; Semlitsch B; Pieber TR
    Diabetes Obes Metab; 2014 Jan; 16(1):57-62. PubMed ID: 23841569
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of type 2 diabetes mellitus on the pharmacokinetics of berberine in rats.
    Jia Y; Xu B; Xu J
    Pharm Biol; 2017 Dec; 55(1):510-515. PubMed ID: 27937081
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetic and pharmacodynamic differences of new generation, longer-acting basal insulins: potential implications for clinical practice in type 2 diabetes.
    Hompesch M; Patel DK; LaSalle JR; Bolli GB
    Postgrad Med; 2019 Mar; 131(2):117-128. PubMed ID: 30691343
    [TBL] [Abstract][Full Text] [Related]  

  • 27.
    Schiavon M; Visentin R; Giegerich C; Sieber J; Dalla Man C; Cobelli C; Klabunde T
    Diabetes Technol Ther; 2020 Aug; 22(8):553-561. PubMed ID: 32125178
    [No Abstract]   [Full Text] [Related]  

  • 28. [Therapeutic compliance and flexibility in the use of basal insulins].
    Costa Gil JE; Litwak LE; Fuente GV; Faingold MC
    Medicina (B Aires); 2014; 74(4):273-81. PubMed ID: 25188652
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Integrating advances in insulin into clinical practice: Overview of current insulin formulations.
    Rhinehart AS
    J Fam Pract; 2013 Sep; 62(9 Suppl Insulin):S4-8. PubMed ID: 24080572
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Duration of action and pharmacokinetics of the oral antidiabetic drug gliquidone in patients with non-insulin-dependent (type 2) diabetes mellitus.
    von Nicolai H; Brickl R; Eschey H; Greischel A; Heinzel G; König E; Limmer J; Rupprecht E
    Arzneimittelforschung; 1997 Mar; 47(3):247-52. PubMed ID: 9105542
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Faster-acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart.
    Heise T; Hövelmann U; Brøndsted L; Adrian CL; Nosek L; Haahr H
    Diabetes Obes Metab; 2015 Jul; 17(7):682-8. PubMed ID: 25846340
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics and pharmacodynamics of insulin glargine given in the evening as compared with in the morning in type 2 diabetes.
    Porcellati F; Lucidi P; Cioli P; Candeloro P; Marinelli Andreoli A; Marzotti S; Ambrogi M; Bolli GB; Fanelli CG
    Diabetes Care; 2015 Mar; 38(3):503-12. PubMed ID: 25524950
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Electroporation of polymeric nanoparticles: an alternative technique for transdermal delivery of insulin.
    Rastogi R; Anand S; Koul V
    Drug Dev Ind Pharm; 2010 Nov; 36(11):1303-11. PubMed ID: 20849347
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Insulin degludec: pharmacokinetic properties in subjects with hepatic impairment.
    Kupčová V; Arold G; Roepstorff C; Højbjerre M; Klim S; Haahr H
    Clin Drug Investig; 2014 Feb; 34(2):127-33. PubMed ID: 24277680
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Morning administration of 0.4U/kg/day insulin glargine 300U/mL provides less fluctuating 24-hour pharmacodynamics and more even pharmacokinetic profiles compared with insulin degludec 100U/mL in type 1 diabetes.
    Bailey TS; Pettus J; Roussel R; Schmider W; Maroccia M; Nassr N; Klein O; Bolli GB; Dahmen R
    Diabetes Metab; 2018 Feb; 44(1):15-21. PubMed ID: 29153485
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biochanin A improves insulin sensitivity and controls hyperglycemia in type 2 diabetes.
    Oza MJ; Kulkarni YA
    Biomed Pharmacother; 2018 Nov; 107():1119-1127. PubMed ID: 30257324
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetic-pharmacodynamic analysis of the glucose-lowering effect of metformin in diabetic rats reveals first-pass pharmacodynamic effect.
    Stepensky D; Friedman M; Raz I; Hoffman A
    Drug Metab Dispos; 2002 Aug; 30(8):861-8. PubMed ID: 12124302
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antihyperglycemic, antilipid peroxidation, and insulin secretory activities of Otostegia persica shoot extract in streptozotocin-induced diabetic rats and in vitro C187 pancreatic β-cells.
    Manzari-Tavakoli A; Pouraboli I; Yaghoobi MM; Mehrabani M; Mirtadzadini SM
    Pharm Biol; 2013 Feb; 51(2):253-9. PubMed ID: 23134106
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enhancement of absorption of insulin-loaded polyisobutylcyanoacrylate nanospheres by sodium cholate after oral and subcutaneous administration in diabetic rats.
    Radwan MA
    Drug Dev Ind Pharm; 2001 Oct; 27(9):981-9. PubMed ID: 11763477
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of sulfobutyl ether-β-cyclodextrin on bioavailability of insulin glargine and blood glucose level after subcutaneous injection to rats.
    Uehata K; Anno T; Hayashida K; Motoyama K; Hirayama F; Ono N; Pipkin JD; Uekama K; Arima H
    Int J Pharm; 2011 Oct; 419(1-2):71-6. PubMed ID: 21803140
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.